Does Cosentyx Dosage Depend on Weight?
Cosentyx (secukinumab) dosing follows fixed schedules based on the condition treated, not patient weight. Adults receive 300 mg subcutaneous injections at weeks 0, 1, 2, 3, and 4, then every 4 weeks. This applies to plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, regardless of body weight.[1][2]
Adjustments for Children and Adolescents
For pediatric plaque psoriasis patients aged 6 and older weighing at least 50 kg, dosing matches the adult 300 mg regimen (two 150 mg injections). Children weighing 15-49.9 kg get 150 mg (one injection). Those under 15 kg are not approved. Weight bands ensure age-appropriate exposure, as lighter children metabolize differently.[1][3]
| Weight Range (Pediatric Psoriasis) | Starting Dose | Maintenance Dose |
|----------------------------|---------------|------------------|
| <15 kg | Not approved | Not approved |
| 15-49.9 kg | 150 mg (wk 0-4) | 150 mg every 4 weeks |
| ≥50 kg | 300 mg (wk 0-4) | 300 mg every 4 weeks |
Why Fixed Dosing for Adults?
Fixed doses simplify administration and avoid weight-based calculations, which could complicate self-injection. Clinical trials showed consistent efficacy and safety across BMI ranges up to 40 kg/m², with no need for weight adjustments in adults.[2][4] Higher body weight correlates with slightly lower drug exposure, but response rates remain similar.
What If Weight Changes During Treatment?
No formal guidance exists for weight gain or loss. Doctors monitor response clinically; if efficacy drops (e.g., in obese patients), they may increase frequency off-label or switch therapies, though evidence is limited.[4][5]
Common Concerns for Overweight Patients
Overweight adults may have reduced serum concentrations due to larger volume of distribution, potentially lowering response rates by 10-20% in psoriasis trials. Still, guidelines do not adjust doses.[4][6] No increased toxicity risk with fixed dosing.
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Secukinumab
[3]: EMA Cosentyx Summary of Product Characteristics
[4]: Blauvelt et al., J Am Acad Dermatol (2017) - Secukinumab exposure-response in psoriasis
[5]: Clinical Pharmacology Review, FDA Approval Package
[6]: Warren et al., Br J Dermatol (2018) - BMI impact on biologics